Eugenia Wong1, Shoshana H Ballew2, Natalie Daya2, Junichi Ishigami2, Casey M Rebholz2, Kunihiro Matsushita2,3, Morgan E Grams2,3, Josef Coresh2,3. 1. Department of Epidemiology, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, eugeniasw@unc.edu. 2. Department of Epidemiology, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 3. Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
INTRODUCTION: Chronic kidney disease (CKD) risk staging is based on estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR). However, the relationship between all-cause hospitalization risk and the current CKD staging system has not been well studied among older adults, despite a high prevalence of CKD and a high risk of hospitalization in old age. METHODS: Among 4,766 participants of the Atherosclerosis Risk in Communities study, CKD was staged according to Kidney Disease Improving Global Outcomes (KDIGO) criteria, using creatinine-based eGFR (eGFRcr) and ACR. Incidence rates of all-cause hospitalization associated with each CKD risk group were analyzed using negative binomial regression. Additionally, cause-specific hospitalization risks for cardiovascular, infectious, kidney, and other diseases were estimated. The impacts of using cystatin C-based eGFR (eGFRcys) to estimate the prevalence of CKD and risks of hospitalization were also quantified. RESULTS: Participants experienced 5,548 hospitalizations and 29% had CKD. Hospitalization rates per 1,000 person-years according to KDIGO risk categories were 208-223 ("low risk"), 288-376 ("moderately increased risk"), 363-548 ("high risk"), and 499-1083 ("very high risk"). The increased risk associated with low eGFR and high ACR persisted in adjusted analyses, examinations of cause-specific hospitalizations, and when CKD was staged by eGFRcys or eGFRcr-cys, a combined equation based on both creatinine and cystatin C. In comparison to eGFRcr, staging by eGFRcys increased the prevalence of CKD to 50%, but hospitalization risks remained similarly high. DISCUSSION/ CONCLUSION: In older adults, decreased eGFR, increased ACR, and KDIGO risk stages based on a combination of these measures, were strong risk factors for hospitalization. These relationships were consistent, regardless of the marker used to estimate GFR, but the use of cystatin C resulted in a substantially higher prevalence of CKD than the use of creatinine. Older adults in the population with very high risk stages of CKD have hospitalization rates exceeding 500 per 1,000 person-years.
INTRODUCTION:Chronic kidney disease (CKD) risk staging is based on estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR). However, the relationship between all-cause hospitalization risk and the current CKD staging system has not been well studied among older adults, despite a high prevalence of CKD and a high risk of hospitalization in old age. METHODS: Among 4,766 participants of the Atherosclerosis Risk in Communities study, CKD was staged according to Kidney Disease Improving Global Outcomes (KDIGO) criteria, using creatinine-based eGFR (eGFRcr) and ACR. Incidence rates of all-cause hospitalization associated with each CKD risk group were analyzed using negative binomial regression. Additionally, cause-specific hospitalization risks for cardiovascular, infectious, kidney, and other diseases were estimated. The impacts of using cystatin C-based eGFR (eGFRcys) to estimate the prevalence of CKD and risks of hospitalization were also quantified. RESULTS:Participants experienced 5,548 hospitalizations and 29% had CKD. Hospitalization rates per 1,000 person-years according to KDIGO risk categories were 208-223 ("low risk"), 288-376 ("moderately increased risk"), 363-548 ("high risk"), and 499-1083 ("very high risk"). The increased risk associated with low eGFR and high ACR persisted in adjusted analyses, examinations of cause-specific hospitalizations, and when CKD was staged by eGFRcys or eGFRcr-cys, a combined equation based on both creatinine and cystatin C. In comparison to eGFRcr, staging by eGFRcys increased the prevalence of CKD to 50%, but hospitalization risks remained similarly high. DISCUSSION/ CONCLUSION: In older adults, decreased eGFR, increased ACR, and KDIGO risk stages based on a combination of these measures, were strong risk factors for hospitalization. These relationships were consistent, regardless of the marker used to estimate GFR, but the use of cystatin C resulted in a substantially higher prevalence of CKD than the use of creatinine. Older adults in the population with very high risk stages of CKD have hospitalization rates exceeding 500 per 1,000 person-years.
Authors: Guruprasad Manjunath; Hocine Tighiouart; Josef Coresh; Bonnie Macleod; Deeb N Salem; John L Griffith; Andrew S Levey; Mark J Sarnak Journal: Kidney Int Date: 2003-03 Impact factor: 10.612
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Matthew T James; Hude Quan; Marcello Tonelli; Braden J Manns; Peter Faris; Kevin B Laupland; Brenda R Hemmelgarn Journal: Am J Kidney Dis Date: 2009-05-17 Impact factor: 8.860
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; Linda F Fried; Anne B Newman; David S Siscovick; Lesley Stevens; Mark J Sarnak Journal: Am J Nephrol Date: 2009-04-07 Impact factor: 3.754
Authors: P E Stevens; D J O'Donoghue; S de Lusignan; J Van Vlymen; B Klebe; R Middleton; N Hague; J New; C K T Farmer Journal: Kidney Int Date: 2007-04-18 Impact factor: 10.612
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Sarah J Ramer; Nicolas A Baddour; Edward D Siew; Huzaifah Salat; Aihua Bian; Thomas G Stewart; Susan P Y Wong; Manisha Jhamb; Khaled Abdel-Kader Journal: Am J Nephrol Date: 2020-07-28 Impact factor: 3.754
Authors: Julie M Paik; Elisabetta Patorno; Min Zhuo; Lily G Bessette; Cassandra York; Nileesa Gautam; Dae Hyun Kim; Seoyoung C Kim Journal: Pharmacoepidemiol Drug Saf Date: 2021-12-23 Impact factor: 2.890
Authors: Joshua I Barzilay; Petra Buzkova; Michael G Shlipak; Nisha Bansal; Pranav Garimella; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Rasheeda K Hall; Jacob B Blumenthal; Rebecca M Doerfler; Jing Chen; Clarissa J Diamantidis; Bernard G Jaar; John W Kusek; Krishna Kallem; Mary B Leonard; Sankar D Navaneethan; Daohang Sha; James H Sondheimer; Lee-Ann Wagner; Wei Yang; Min Zhan; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2021-05-23 Impact factor: 11.072
Authors: Alliny Sales Rodrigues; Luiz Carlos de Abreu; Mauro Jose de Deus Morais; Francisco Naildo Cardoso Leitao; Gardenia Lima Gurgel do Amaral; Edige Felipe de Sousa Santos; Ricardo Peres do Souto Journal: Medicine (Baltimore) Date: 2022-07-01 Impact factor: 1.817